γδT cells: alternative treasure in antitumor immunity
γδT cells: alternative treasure in antitumor immunity
复制标题
DOI：
10.37349/ei.2022.00035
复制
发表时间：
2022-02
期刊：
影响因子：
--
通讯作者：
Xiangjin Zhang;Yi Xu;Hui Chen;Jianmin Zhang;Wei He
中科院分区：
文献类型：
--
作者：
Xiangjin Zhang;Yi Xu;Hui Chen;Jianmin Zhang;Wei He
近几十年来，针对肿瘤细胞的免疫治疗方法不断发展。最近发现，在血液肿瘤中观察到的优异疗效不能在实体肿瘤中实现，因为会发生严重的副作用。这些都是来自工程适应性免疫细胞，其使用将带来限制。γδT细胞具有响应多种肿瘤细胞的独特能力，同时连接先天免疫和适应性免疫，因此，它们是治疗性同种异体细胞的理想来源。本文综述了γδT细胞临床应用的优化策略，以期为过继免疫治疗提供新的思路。
In recent decades, abundant methods for targeted tumor cell immunotherapy have been developed. It was recently discovered that excellent curative effects observed in hematological tumors cannot be achieved in solid tumors, as serious side effects will occur. These are all derived from engineered adaptive immune cells, the use of which will bring limitations. γδT cells have a unique ability to respond to a variety of tumor cells while linking innate immunity and adaptive immunity, and thus, they are an ideal source of therapeutic allogeneic cells. This review introduces strategies that can optimize the clinical application of γδT cells to provide novel ideas for adoptive immunotherapy in the future.